Advanced antisense therapies for postexposure protection against lethal filovirus infections. - Test2 - elhamkhani - TriplyDB

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

http://www.wikidata.org/entity/Q34132633

about

Animal models for Ebola and Marburg virus infections Assembly of Ebola virus matrix protein VP40 is regulated by latch-like properties of N and C terminal tails The 2014–2015 Ebola outbreak in West Africa: Hands On Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb Emerging targets and novel approaches to Ebola virus prophylaxis and treatment Monitoring of Ebola Virus Makona Evolution through Establishment of Advanced Genomic Capability in Liberia Filoviruses: One of These Things is (not) Like the Other Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks Pre-symptomatic diagnosis and treatment of filovirus diseases Shedding light on filovirus infection with high-content imaging Standardization of the filovirus plaque assay for use in preclinical studies Mouse models for filovirus infections Delayed Time-to-Treatment of an Antisense Morpholino Oligomer Is Effective against Lethal Marburg Virus Infection in Cynomolgus Macaques Serosurveillance of viral pathogens circulating in West Africa Lymphocytic choriomeningitis virus infection in FVB mouse produces hemorrhagic disease Ebola virus: A gap in drug design and discovery - experimental and computational perspective.Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.Could the Ebola virus matrix protein VP40 be a drug target?Potential clinical treatment for Ebola pandemic.The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target.CHO cell production and sequence improvement in the 13C6FR1 anti-Ebola antibody.Identification of essential filovirion-associated host factors by serial proteomic analysis and RNAi screen.Possible leap ahead in filovirus therapeutics.Post-exposure treatment of non-human primates lethally infected with Ebola virus with EBOTAb, a purified ovine IgG product.Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430.Infection control during filoviral hemorrhagic Fever outbreaks.RNA therapeutics: beyond RNA interference and antisense oligonucleotides.Therapeutics for filovirus infection: traditional approaches and progress towards in silico drug design.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp Safety and pharmacokinetic profiles of phosphorodiamidate morpholino oligomers with activity against ebola virus and marburg virus: results of two single-ascending-dose studies.Medical research: Ebola therapy protects severely ill monkeys.Distinct lineages of Ebola virus in Guinea during the 2014 West African epidemic.Ebola hemorrhagic fever: current outbreak and progress in finding a cure.Euthanasia assessment in ebola virus infected nonhuman primates.Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies.Evaluation of the potential impact of Ebola virus genomic drift on the efficacy of sequence-based candidate therapeutics.A single phosphorodiamidate morpholino oligomer targeting VP24 protects rhesus monkeys against lethal Ebola virus infection Basic peptide-morpholino oligomer conjugate that is very effective in killing bacteria by gene-specific and nonspecific modes.Clinical aspects of Marburg hemorrhagic fever Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak

P2860

Q21131118-FBA830B5-84BE-4F84-8B33-F3A6A42F7EDA Q21134356-E967E667-2867-4039-BF24-CA1D1B99B9EE Q24049114-4EBFF2A2-AC37-44C2-B714-A310C75A0F8D Q24594601-50CD3CC7-8A52-4469-B9CF-A63EDCE496ED Q24597625-B84CF815-445A-4D7A-98FF-91FDDA44B7DF Q24696012-5F4A3932-F56D-4A00-8821-CE68CDD4A129 Q26783063-F9C765DF-573F-453F-95CE-D422B23C1304 Q26801423-54BBBA63-E75E-4E97-B827-606ACC33CFFF Q26823831-765C3E4F-D7FB-4D21-A599-459E14F39A11 Q26863739-45C6140D-354E-4D16-B023-C5380832F607 Q27000207-573FA377-8585-498C-84A0-334E04BA240A Q27011569-22A4CE6E-566D-4FD0-B13B-8303E9681B03 Q27303778-01F53B1E-04F6-45C0-BE4C-697F3177A5B3 Q27468590-B2D9B148-23FD-436F-A11D-EB3D5783F01F Q28484627-F3FE95A2-3272-4122-924A-7B9A7ED9A82C Q30243938-FF24A75A-2CD7-40DD-BB24-D260B44E6F4E Q30251949-E780E9A5-7302-488F-AD41-339C789B8AA7 Q30356113-D5A56A2E-5A37-4D21-8EEB-C765E5090A22 Q30366997-A984D5B4-AB8B-438B-8ECD-1711266F2116 Q30376138-EF8B2D7B-6770-4D04-A5E1-1CB3CB315114 Q30383481-06AFE171-3EB4-4664-8870-285249A63955 Q33655087-4E43A187-56CB-452A-81AC-9E369FD61D1D Q33701830-D6AADFCC-DDAE-482A-AD08-45A6AAE8989F Q33826350-3E65C1EB-E080-4B04-8137-1636A83D59C2 Q34040052-E5DEB660-C26B-4D26-AA12-B749F78125B1 Q34243483-E7057716-71B8-4956-A2DD-0B1D264443D6 Q34248493-7E726498-31E1-4F1A-BC0E-EAE93B22D531 Q34371001-82DA8147-D51B-4D97-9885-FD128B292A4A Q34426585-7A571573-233A-47AD-A01E-66376719585A Q34435035-E50CE069-E988-4607-B70C-AEEEFE0F48F9 Q34435933-C0F106FB-D543-4F53-B9EB-2EA2FD801655 Q34482091-D19D261C-B80D-45EE-8C05-90E442385E92 Q34491250-CCC27595-2BA2-49CD-BFEB-6C1E55B13516 Q34580900-52C138E5-51E9-4420-A093-D0451283E1AF Q34971349-9F7CC7E2-FA17-490A-A882-B94CDB9E8467 Q35038226-7D36639D-0108-4679-B0A9-F82853145170 Q35111132-8CBD6591-5A0A-4F7E-BF7C-1CB58BB3BB5C Q35289367-CC58AADE-6FA0-4E32-9CE6-21A9149711EE Q35446144-F52A0B09-74AE-4751-94ED-FD0FB163B463 Q35598919-64B0A411-F9F9-4A78-8538-11482470C0BD

P2860

Advanced antisense therapies for postexposure protection against lethal filovirus infections.

http://www.wikidata.org/entity/Q34132633

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Advanced antisense therapies f ...... t lethal filovirus infections.

@ast

Advanced antisense therapies f ...... t lethal filovirus infections.

@en

Advanced antisense therapies f ...... t lethal filovirus infections.

@nl

type

label

Advanced antisense therapies f ...... t lethal filovirus infections.

@ast

Advanced antisense therapies f ...... t lethal filovirus infections.

@en

Advanced antisense therapies f ...... t lethal filovirus infections.

@nl

prefLabel

Advanced antisense therapies f ...... t lethal filovirus infections.

@ast

Advanced antisense therapies f ...... t lethal filovirus infections.

@en

Advanced antisense therapies f ...... t lethal filovirus infections.

@nl

P1433

Q34132633-5FA30A60-796D-476D-B17B-D5BBE67C41FF

P1476

Q34132633-1157948D-7D75-4F70-8441-D26789665D0F

P2093

Q34132633-2A0CDB81-2710-49FF-96DB-5F1132BF4C9B

Q34132633-2C49DDB4-9BAE-4827-A0B4-0A78EDCCB9F9

Q34132633-3E4D5A5E-8756-4DAB-BFD3-27F5518E978C

Q34132633-42DA1F6B-7363-44F4-BFFE-527380E6E9BF

Q34132633-5F473679-9318-40C3-A95C-02DCDC06BB3C

Q34132633-5FCCE284-0F8B-4151-A9B8-739F7BFB67D2

Q34132633-612DD057-640A-4384-B6D4-81375ABA5FDF

Q34132633-99A7512C-B091-456B-94C2-4DC2D243905A

Q34132633-9C1E63BC-AF61-4F3B-BE14-79AE983B671E

Q34132633-A5ADAF01-AAAA-4753-AAA4-A5B0DE380C56

P2860

Q34132633-B1BA5DC1-4A69-4834-BA71-0A61D4DA5E10

Q34132633-DDED97F1-F760-4964-B298-A2DBD5F2D09B

P2888

Q34132633-FDA4CB7F-3812-4484-84CC-353AC5752749

P304

Q34132633-0EF17EFE-2858-4C0B-897D-1BCAAAA7FA38

P31

Q34132633-04022CC9-29BE-484C-A9BC-FC2F4470DF6A

P356

Q34132633-82CD243C-107F-4740-B230-558926856314

P407

Q34132633-799DD417-9DDB-4EF9-9E75-1CB7D5B3C892

P433

Q34132633-6D1E7FDA-EDB6-4E41-A576-787511DADF5D

P478

Q34132633-3A06CE4E-4E57-4115-894D-3F6999CCA66D

P50

Q34132633-98173101-42E2-4989-8F0A-D631280FC27F

Q34132633-9E0404DB-F33F-460B-A9E7-AE62B857DB09

P577

Q34132633-FB1AAD56-D958-4BC4-8D29-F59FECFF8B0E

P5875

Q34132633-6436414B-A945-469F-B82A-D803341039A4

P698

Q34132633-1542ACDC-AB39-4617-B1A5-7335242BFE93

P356

P1433

Nature Medicine

P1476

Advanced antisense therapies f ...... st lethal filovirus infections

@en

P2093

Dan V Mourich

http://www.w3.org/2001/XMLSchema#string

Dana L Swenson

http://www.w3.org/2001/XMLSchema#string

Donald K Nichols

http://www.w3.org/2001/XMLSchema#string

Jay Wells

http://www.w3.org/2001/XMLSchema#string

Kelly L Warfield

http://www.w3.org/2001/XMLSchema#string

Kelly S Donner

http://www.w3.org/2001/XMLSchema#string

Lian Dong

http://www.w3.org/2001/XMLSchema#string

Nicole L Garza

http://www.w3.org/2001/XMLSchema#string

Sean A Van Tongeren

http://www.w3.org/2001/XMLSchema#string

Stacy Crumley

http://www.w3.org/2001/XMLSchema#string

P2860

Pathophysiology of shock and hemorrhage in a fulminating viral infection (Ebola).

Postexposure treatment of Marburg virus infection

P2888

P304

991-994

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.2202

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Patrick L Iversen

P577

2010-08-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45800284

http://www.w3.org/2001/XMLSchema#string

P698

20729866

http://www.w3.org/2001/XMLSchema#string